Varshini Babu

Varshini Babu

Auto-generated profile, based on publicly available information

Varshini Babu

Department of Dermatology Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
VBVarshini Babu
Varshini Babu
JLJane A. Little
Jane A. Little
CMClaudia R. Morris
Claudia R. Morris
RMRoberto Machado
Roberto Machado
SGSimon Gibbs
Simon Gibbs
Seyed NouraieSeyed Nouraie
Seyed Nouraie


1 September 2026 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
VBVarshini Babu
Varshini Babu
DMDavid J. Margolis
David J. Margolis
RBRonald Berna
Ronald Berna

26 August 2024
Verified
Preprint
Open access
VBVarshini Babu
Varshini Babu
JLJane Little
Jane Little
CMClaudia R. Morris
Claudia R. Morris
RMRobert Machado
Robert Machado
SGSimon Gibbs
Simon Gibbs
YZYingze Zhang
Yingze Zhang
Purpose: Pulmonary hypertension (PH) is a chronic complications of sickle cell disease (SCD) with limited known biomarkers, beyond increases in plasma brain natriuretic peptide levels. Experimental Design: We conducted a proof-of-concept study to identify serum protein biomarkers that were differentially expressed in SCD patients with elevated tricuspid regurgitation velocity (TRV – a noninvasive marker of PH). Results: We found 41 out of 92 target proteins that were significantly different between the non-elevated (TRV≤2.6 m/sec; N = 35) and highly elevated TRV group (TRV≥2.9 m/sec; N = 35, p<0.05). Six of them passed a Bonferroni correction (p value < 0.0005) including T-cell surface glycoprotein, lymphotactin, SLAM family member 7, galectin-9, TNF-related apoptosis-inducing ligand receptor 2, and tumor necrosis factor receptor superfamily member 11A . We observed up to a 1.2-fold increase in the high TRV group for these six proteins. These six proteins had strong positive correlation with serum NT-proBNP levels (a positive control marker elevated in PH (r >= 0.44). Additionally, these markers correlated with other clinical parameters of PH in SCD. Conclusion: Circulatory protein markers of the immune response are increased in SCD patients with elevated TRV as compared to those without elevated TRV.